Schroder UK Public Private Tst plc Investment in Anthos Therapeutics (3619K)

TIDMSUPP

RNS Number : 3619K

Schroder UK Public Private Tst plc

20 December 2022

Schroder UK Public Private Trust plc

Investment in Anthos Therapeutics

Schroder UK Public Private Trust plc (the "Company") is pleased to announce it has made a commitment of $2.8 million (GBP2.3 million) to US-based, clinical-stage biopharmaceutical company, Anthos Therapeutics LLC ("Anthos"), in its Series B financing round.

Anthos' mission is to develop innovative therapies to advance care for people living with cardiovascular and metabolic diseases. Their most advanced program is focused on developing abelacimab, an investigational monoclonal antibody that inhibits coagulation Factor XI and its activated form, Factor XIa. Abelacimab is an experimental, next-generation anticoagulant with the potential to provide 'hemostasis-sparing anticoagulation': protection from arterial and venous thromboembolic events with a reduced risk of clinically-significant bleeding.

The Company is committed to reporting on its sustainability profile and discloses, where appropriate, the United Nations' Sustainable Development Goals ("SDGs") associated with all investments. The investment in Anthos is in line with SDG 3 "Good health and well-being", specifically Target 3.4 "Reduce mortality from non-communicable diseases and promote mental health" and Target 3.B "Support research, development and universal access to affordable vaccines and medicines".

The investment in Anthos is in line with the Company's private equity sub-strategy for backing innovative life sciences businesses, at the clinical or near-clinical stage, with high quality science and, a strong financing position.

Enquiries:

Schroder Investment Management Limited

 
 Augustine Chipungu (Press)     0207 658 2106 
 John Spedding                  0207 658 3206

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ACQFLFEVFTLIFIF

(END) Dow Jones Newswires

December 20, 2022 08:59 ET (13:59 GMT)

Woodford Patient Capital (LSE:WPCT)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024